Tae Jin Ahn

Title: Inventor Profile: Tae Jin Ahn

Introduction

Tae Jin Ahn is a notable inventor based in Seoul, South Korea, recognized for his contributions in the field of biotechnology. With a total of four patents to his name, he has made significant advancements in predicting the effects of certain antibodies and inhibitors, which play crucial roles in cancer treatment.

Latest Patents

Among his latest innovations, Tae Jin Ahn has developed a biomarker for predicting the effect of an anti-c-Met antibody. His method involves measuring the level of this biomarker in a biological sample, allowing for more accurate predictions regarding treatment outcomes. Additionally, he has created a biomarker known as TFF1, which is instrumental in predicting the effect of a c-Met inhibitor. This includes methods for monitoring the effect of such an inhibitor and treating or preventing cancer by administering the inhibitor to selected subjects based on biomarker analysis.

Career Highlights

Tae Jin Ahn is currently affiliated with Samsung Electronics Co., Ltd., a leading global technology company. His work at Samsung emphasizes the integration of biological research with innovative technological solutions, pushing the boundaries of medical science through patentable inventions.

Collaborations

Throughout his career, Tae Jin Ahn has collaborated with talented coworkers such as Taejoon Park and Eunjin Lee. These partnerships have further enhanced the research and development processes behind his groundbreaking patents, leading to greater advancements in their respective field.

Conclusion

Tae Jin Ahn's contributions to biotechnology exemplify the critical intersection of innovation and healthcare. With his patents focusing on predictive biomarkers and cancer treatments, his work continues to impact the scientific community, aiming to improve patient outcomes in oncology. As he forges ahead in his career, the future of his innovations remains bright and promising.